Shares of hVIVO plc (LON:HVO - Get Free Report) were down 45.1% during trading on Friday . The company traded as low as GBX 6.50 ($0.09) and last traded at GBX 8.89 ($0.12). Approximately 79,176,703 shares were traded during mid-day trading, an increase of 2,238% from the average daily volume of 3,386,887 shares. The stock had previously closed at GBX 16.20 ($0.22).
Wall Street Analysts Forecast Growth
Separately, Shore Capital reiterated a "buy" rating on shares of hVIVO in a report on Friday.
Read Our Latest Research Report on HVO
hVIVO Price Performance
The stock's fifty day moving average price is GBX 16.16 and its 200-day moving average price is GBX 18.13. The firm has a market cap of £61.56 million, a price-to-earnings ratio of 3.59 and a beta of 0.97. The company has a current ratio of 1.61, a quick ratio of 1.16 and a debt-to-equity ratio of 33.86.
hVIVO (LON:HVO - Get Free Report) last announced its quarterly earnings results on Thursday, April 10th. The company reported GBX 1.69 ($0.02) earnings per share (EPS) for the quarter. hVIVO had a net margin of 25.96% and a return on equity of 47.93%. As a group, equities research analysts forecast that hVIVO plc will post 1.5492958 earnings per share for the current fiscal year.
Insider Transactions at hVIVO
In related news, insider Yamin Mo' Khan sold 3,062,246 shares of hVIVO stock in a transaction that occurred on Thursday, March 6th. The shares were sold at an average price of GBX 17 ($0.23), for a total value of £520,581.82 ($700,459.93). Insiders own 14.03% of the company's stock.
About hVIVO
(
Get Free Report)
hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.
See Also
Before you consider hVIVO, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and hVIVO wasn't on the list.
While hVIVO currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
